Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With EGFR Exon 20 Insertion Mutation: A Case Report

Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With EGFR Exon 20 Insertion Mutation: A Case Report

Amivantamab is the first drug approved in EGFR exon 20 insertion-mutated NSCLC. Nevertheless, primary or secondary resistance to amivantamab is a frequent problem in clinical practice. We report a case of a patient with EGFR exon 20-mutated NSCLC who had primary resistance to amivantamab but was suc...

Full description

Bibliographic Details
Main Authors: Jaemin Kim, BS, Youngjoo Lee, MD, PhD
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:JTO Clinical and Research Reports
Subjects:
NSCLC
EGFR exon 20 insertion
Drug resistance
Anti-angiogenesis
Targeted therapy
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323001431

Internet

http://www.sciencedirect.com/science/article/pii/S2666364323001431

Similar Items